Gilead Adefovir Hep B Resistance Potential Shows Need For Combo Trials

Gilead adefovir combination studies could address concerns about the potential for developing viral resistance with single-agent use of the drug for chronic hepatitis B, Gilead VP-Clinical Research Carol Brosgart, MD, told an FDA advisory committee Aug. 6